Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer reports Q1 2022 revenue of $1.26 billion, down from $1.31 billion a year prior. GAAP EPS from continuing operations is $1.40 compared to $3.37 in Q1 2021. The company initiates guidance for Q2 2022, forecasting revenue of $1.20-1.22 billion and expects adjusted EPS between $2.00-2.05. For the full year, expected revenue is $4.56-4.63 billion with adjusted EPS of $7.15-7.45. Despite revenue declines, the company highlights significant growth in the Discovery & Analytical Solutions segment with a 33% increase.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, to be paid on August 12, 2022. This dividend is for shareholders on record as of July 22, 2022. In 2021, the company reported approximately $5 billion in revenue and employs over 16,000 individuals, serving customers across 190 countries. PerkinElmer is part of the S&P 500 Index, indicating its significant presence in the market.
PerkinElmer, Inc. (NYSE: PKI) will announce its first quarter 2022 financial results after market close on May 3, 2022. The company will host a conference call that same day at 5:00 p.m. ET to discuss the results, led by CEO Prahlad Singh and CFO Jamey Mock. Investors can access the call through a live audio webcast available on the company's website, with a replay starting at 7:00 p.m. ET the same day. PerkinElmer reported approximately $5.0 billion in revenue in 2021 and operates in 190 countries.
PerkinElmer, Inc. (NYSE: PKI) has launched the Vega® imaging system, an innovative automated ultrasound platform aimed at enhancing preclinical research in cancer, liver and kidney diseases, and cardiology. The system allows for hands-free operation and high-throughput scanning, improving research efficiency. Key features include advanced imaging modes for better visualization of diseases and therapies. This technology was acquired through PerkinElmer's purchase of SonoVol, Inc. The company recently reported revenues near $5 billion in 2021, supporting its position in the S&P 500.
PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.
PerkinElmer, a leader in health innovation, will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference. The Cowen conference is scheduled for March 7, 2022, with Jamey Mock, CFO, presenting at 10:30 a.m. ET. Following this, Prahlad Singh, CEO, will present at the Barclays conference on March 15, 2022, at 1:30 p.m. ET in Miami. Both presentations will provide insights on the company's strategic priorities, with live audio webcasts available on their website, where replays will also be accessible for 90 days post-event.
PerkinElmer, a leader in health innovation, will present at Citi’s Virtual Healthcare Conference on February 24, 2022, at 8:45 a.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. Interested participants can register here. A live webcast will also be available on the Investors section of the company’s website, with a replay accessible for 90 days post-event.
PerkinElmer reported $5.0 billion in revenue for 2021 and operates in 190 countries.
EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.
PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.
The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of
FAQ
What is the market cap of PERKINELMER (PKI)?
